PHT Adopts Vodafone M2M Tech
Vodafone’s Machine-to-Machine (M2M) technology enables PHT Corporation to more efficiently manage worldwide clinical trials through real-time access to patient experience data
Vodafone and PHT Corporation, a provider of technologies used to collect electronic data for clinical research from patients, will connect the PHT electronic clinical outcome assessment (eCOA) system to Vodafone’s global M2M network. Using Vodafone’s global M2M network, PHT can provide pharmaceutical trial sponsors real-time access to patient data. Currently the PHT eCOA System is used to collect data in clinical trials in more than 75 countries.
Read the full release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.
